ATR Stock Analysis: AptarGroup | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 8.571m USD | 12M Return: -2% | US0383361039 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 64.9M
EPS Trend: 82.0%
Qual. Beats: 1
Rev. Trend: 92.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AptarGroup, Inc. (NYSE: ATR) is a U.S.-based packaging manufacturer that designs and produces drug delivery, consumer dispensing, and active material science solutions across three reporting segments: Pharma, Beauty, and Closures. Its product portfolio includes dispensing pumps, fine-mist and lotion pumps, aerosol valves, elastomeric primary packaging components, closures, and digital health solutions, serving end markets such as pharmaceuticals, fragrance, skincare, color cosmetics, personal care, home care, and food and beverage. The company sells globally across Asia, Europe, Latin America, and North America, and was incorporated in 1992 in Crystal Lake, Illinois, with a 1993 IPO.
The business operates within the GICS Materials sector, specifically the Metal, Glass & Plastic Containers sub-industry, reflecting its core role as a specialty packaging supplier rather than a pure packaging commodities producer. Its segment structure is notable for pairing a regulated Pharma business (drug delivery devices, elastomeric components, and digital health) with consumer-facing Beauty and Closures operations, combining B2B sales into pharmaceutical and CPG manufacturers across multiple geographies.
- Pharma drug delivery segment drives margin expansion
- Beauty dispensing sales weaken on soft European consumer demand
- Resin and raw material costs pressure packaging margins
| Net Income: 362.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.97 > 1.0 |
| NWC/Revenue: 17.75% < 20% (prev 8.15%; Δ 9.61% < -1%) |
| CFO/TA 0.11 > 3% & CFO 583.5m > Net Income 362.5m |
| Net Debt (1.27b) to EBITDA (822.2m): 1.55 < 3 |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.5m) vs 12m ago -3.79% < -2% |
| Gross Margin: 28.26% > 18% (prev 34.57%; Δ -6.31% > 0.5%) |
| Asset Turnover: 78.68% > 50% (prev 74.21%; Δ 4.46% > 0%) |
| Interest Coverage Ratio: 8.11 > 6 (EBIT TTM 515.0m / Interest Expense TTM 63.5m) |
| A: 0.14 (Total Current Assets 1.83b - Total Current Liabilities 1.14b) / Total Assets 5.13b |
| B: 0.53 (Retained Earnings 2.74b / Total Assets 5.13b) |
| C: 0.10 (EBIT TTM 515.0m / Avg Total Assets 5.00b) |
| D: 1.07 (Book Value of Equity 2.63b / Total Liabilities 2.46b) |
| Altman-Z'' = 4.45 = AA |
| DSRI: 1.03 (Receivables 897.7m/800.2m, Revenue 3.93b/3.61b) |
| GMI: 1.22 (GM 34.57% / 28.26%) |
| AQI: 0.97 (AQ_t 0.31 / AQ_t-1 0.32) |
| SGI: 1.09 (Revenue 3.93b / 3.61b) |
| TATA: -0.04 (NI 362.5m - CFO 583.5m) / TA 5.13b) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of August 26, 2026, the stock is trading at USD 134.75 with a total of 282,301 shares traded. Over the past week, the price has changed by +2.28%, over one month by +2.17%, over three months by +16.19% and over the past year by -1.98%.
Current recommended Stop Loss: 131.10 (which is 2.7% or 1.2 ATR below the current price).
AptarGroup has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ATR.
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 170.1 | 26.3% |
P/E Trailing = 24.3321
P/E Forward = 17.4825
P/S = 2.1791
P/B = 3.261
P/EG = 2.4283
Revenue TTM = 3.93b USD
EBIT TTM = 515.0m USD
EBITDA TTM = 822.2m USD
Long Term Debt = 1.14b USD (from longTermDebt, last fiscal year)
Short Term Debt = 249.2m USD (from shortTermDebt, last quarter)
Debt = 1.47b USD (from shortLongTermDebtTotal, last quarter) + Leases 44.0m
Net Debt = 1.27b USD (calculated: Debt 1.47b - CCE 197.3m)
Enterprise Value = 9.84b USD (8.57b + Debt 1.47b - CCE 197.3m)
Interest Coverage Ratio = 8.11 (Ebit TTM 515.0m / Interest Expense TTM 63.5m)
EV/FCF = 31.72x (Enterprise Value 9.84b / FCF TTM 310.4m)
FCF Yield = 3.15% (FCF TTM 310.4m / Enterprise Value 9.84b)
FCF Margin = 7.89% (FCF TTM 310.4m / Revenue TTM 3.93b)
Net Margin = 9.22% (Net Income TTM 362.5m / Revenue TTM 3.93b)
Gross Margin = 28.26% ((Revenue TTM 3.93b - Cost of Revenue TTM 2.82b) / Revenue TTM)
Gross Margin QoQ = 27.85% (prev 28.10%)
Tobins Q-Ratio = 1.92 (Enterprise Value 9.84b / Total Assets 5.13b)
Interest Expense / Debt = 4.31% (Interest Expense 63.5m / Debt 1.47b)
Taxrate = 20.15% (91.6m / 454.5m)
NOPAT = 411.2m (EBIT 515.0m * (1 - 20.15%))
Current Ratio = 1.61 (Total Current Assets 1.83b / Total Current Liabilities 1.14b)
Debt / Equity = 0.56 (Debt 1.47b / totalStockholderEquity, last quarter 2.63b)
Debt / EBITDA = 1.55 (Net Debt 1.27b / EBITDA 822.2m)
Debt / FCF = 4.10 (Net Debt 1.27b / FCF TTM 310.4m)
Total Stockholder Equity = 2.68b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.25% (Net Income 362.5m / Total Assets 5.13b)
RoE = 13.52% (Net Income TTM 362.5m / Total Stockholder Equity 2.68b)
RoCE = 13.48% (EBIT 515.0m / Capital Employed (Equity 2.68b + L.T.Debt 1.14b))
RoIC = 10.16% (NOPAT 411.2m / Invested Capital 4.05b)
WACC = 6.82% (E(8.57b)/V(10.0b) * Re(7.40%) + D(1.47b)/V(10.0b) * Rd(4.31%) * (1-Tc(0.20)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -88.43 | Cagr: -1.95%
[DCF] Terminal Value 74.10% ; FCFF base≈322.9m ; Y1≈299.3m ; Y5≈270.3m
[DCF] Fair Price = 47.28 (EV 4.28b - Net Debt 1.27b = Equity 3.01b / Shares 63.6m; r=8.35% [WACC [floored]]; 5y FCF grow -9.13% → 2.50% )
EPS Correlation: 81.96 | EPS CAGR: 8.15% | SUE: 1.02 | # QB: 1
Revenue Correlation: 92.77 | Revenue CAGR: 4.31% | SUE: 0.42 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.48 | Chg30d=+0.88% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=5.52 | Chg30d=+0.36% | Revisions=+12% | GrowthEPS=-3.9% | GrowthRev=+5.4%
EPS next Year (2027-12-31): EPS=6.32 | Chg30d=+0.81% | Revisions=-10% | GrowthEPS=+14.5% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +0% (up=8, down=8)